Interventions of Interest

  • Acoramidis (BridgeBio Pharma, Inc)
  • Vyndamax®/Vyndaqel® (tafamidis) (Pfizer Inc.)
  • Amvuttra® (vutrisiran) (Alnylam Pharmaceuticals, Inc.)

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a type of heart muscle disease that occurs when amyloid fibrils – clumps of misfolded proteins – are deposited into heart tissue and cause it to stiffen. Eventually, the heart cannot fill properly, leading to shortness of breath, heart failure, and death.

For questions please contact Madeline Booth, Program Manager, at

View the Key Stakeholder List.